Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press13610.17650/2313-805X-2018-5-1-53-59EXPERIMENTAL RESEARCHЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯBRCA1 mRNA expression levels as an predictor of response to neoadjuvant chemotherapy in breast cancerЭкспрессия мРНК гена BRCA1 в опухолях молочной железы как предиктор ответа на неоадъювантную химиотерапиюhttps://orcid.org/0000-0001-7419-4512TsyganovM. M.ЦыгановМ. М.
Russian Federation

5 Kooperativnyy Lane, Tomsk 634009

634009 Томск, пер. Кооперативный, 5

TsyganovMM@yandex.ruhttps://orcid.org/0000-0001-8815-2786IbragimovaM. K.ИбрагимоваМ. К.
Russian Federation

5 Kooperativnyy Lane, Tomsk 634009

634009 Томск, пер. Кооперативный, 5

https://orcid.org/0000-0002-9568-3371DeryushevaI. V.ДерюшеваИ. В.
Russian Federation

5 Kooperativnyy Lane, Tomsk 634009

634009 Томск, пер. Кооперативный, 5

https://orcid.org/0000-0002-2953-0350KazantsevaP. V.КазанцеваП. В.
Russian Federation

5 Kooperativnyy Lane, Tomsk 634009

634009 Томск, пер. Кооперативный, 5

https://orcid.org/0000-0002-2917-8158GarbukovE. Yu.ГарбуковЕ. Ю.
Russian Federation

5 Kooperativnyy Lane, Tomsk 634009

634009 Томск, пер. Кооперативный, 5

https://orcid.org/0000-0003-4382-5697SlonimskayaE. M.СлонимскаяЕ. М.
Russian Federation

5 Kooperativnyy Lane, Tomsk 634009

634009 Томск, пер. Кооперативный, 5

https://orcid.org/0000-0002-0714-8927LitviakovN. V.ЛитвяковН. В.
Russian Federation

5 Kooperativnyy Lane, Tomsk 634009

634009 Томск, пер. Кооперативный, 5

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesНаучно-исследовательский институт онкологии ФГБНУ «Томский национальный исследовательский медицинский центр Российской академии наук»150120185153591405201814052018Copyright ©; 2018, Tsyganov M.M., Ibragimova M.K., Deryusheva I.V., Kazantseva P.V., Garbukov E.Y., Slonimskaya E.M., Litviakov N.V.Copyright ©; 2018, Цыганов М.М., Ибрагимова М.К., Дерюшева И.В., Казанцева П.В., Гарбуков Е.Ю., Слонимская Е.М., Литвяков Н.В.2018Tsyganov M.M., Ibragimova M.K., Deryusheva I.V., Kazantseva P.V., Garbukov E.Y., Slonimskaya E.M., Litviakov N.V.Цыганов М.М., Ибрагимова М.К., Дерюшева И.В., Казанцева П.В., Гарбуков Е.Ю., Слонимская Е.М., Литвяков Н.В.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/136

breast cancergenes expressionBRCA1neoadjuvant chemotherapychemotherapy efficacyрак молочной железыэкспрессия геновBRCA1неоадъювантная химиотерапияэффективность химиотерапииРабота выполнена в рамках конкурса 2018–2020 гг. на получение стипендии Президента РФ молодым ученым и аспирантам.1. Johnson N., Fletcher O., Palles C. et al. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet 2007;16(9):1051–7. DOI: 10.1093/hmg/ddm050. PMID: 17341484.Johnson N., Fletcher O., Palles C. et al. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. Hum Mol Genet 2007;16(9):1051–7. DOI: 10.1093/hmg/ddm050. PMID: 17341484.2. Kadouri L., Hubert A., Rotenberg Y. et al. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet 2007;44(7):467–71. DOI: 10.1136/jmg.2006.048173. PMID: 17307836.Kadouri L., Hubert A., Rotenberg Y. et al. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. J Med Genet 2007;44(7):467–71. DOI: 10.1136/jmg.2006.048173. PMID: 17307836.3. Simard J., Tonin P., Durocher F. et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 1994;8(4):392–8. DOI: 10.1038/ng1294-392. PMID: 7894492.Simard J., Tonin P., Durocher F. et al. Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet 1994;8(4):392–8. DOI: 10.1038/ng1294-392. PMID: 7894492.4. Palmero E.I., Alemar B., Schüler-Faccini L. et al. Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil. Genet Mol Biol 2016;39(2):210–22. DOI: 10.1590/ 1678-4685-GMB-2014-0363. PMID: 27223485.Palmero E.I., Alemar B., Schüler-Faccini L. et al. Screening for germline BRCA1, BRCA2, TP53 and CHEK2 mutations in families at-risk for hereditary breast cancer identified in a population-based study from Southern Brazil. Genet Mol Biol 2016;39(2):210–22. DOI: 10.1590/ 1678-4685-GMB-2014-0363. PMID: 27223485.5. Byrski T., Huzarski T., Dent R. et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2014;147(2):401–5. DOI: 10.1007/s10549-014-3100-x. PMID: 25129345.Byrski T., Huzarski T., Dent R. et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 2014;147(2):401–5. DOI: 10.1007/s10549-014-3100-x. PMID: 25129345.6. Byrski T., Gronwald J., Huzarski T. et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010;28(3):375–9. DOI: 10.1200/JCO.2008.20.7019. PMID: 20008645.Byrski T., Gronwald J., Huzarski T. et al. Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2010;28(3):375–9. DOI: 10.1200/JCO.2008.20.7019. PMID: 20008645.7. Гафтон И.Г., Имянитов Е.Н., Семиглазов В.В. и др. Экспрессия гена BRCA1 при нейроэндокринных опухолях желудочно-кишечного тракта. Сибирский онкологический журнал 2014;16(4):11–5. [Gafton I.G., Imyanitov E.N., Semiglazov V.V. et al. BRCA1 gene expression in endocrine tumors of the gastrointestinal tract. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2014;16(4):11–5. (In Russ.)].Гафтон И.Г., Имянитов Е.Н., Семиглазов В.В. и др. Экспрессия гена BRCA1 при нейроэндокринных опухолях желудочно-кишечного тракта. Сибирский онкологический журнал 2014;16(4):11–5. [Gafton I.G., Imyanitov E.N., Semiglazov V.V. et al. BRCA1 gene expression in endocrine tumors of the gastrointestinal tract. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2014;16(4):11–5. (In Russ.)].8. Imyanitov E.N., Moiseyenko V.M. Drug therapy for hereditary cancers. Hered Cancer Clin Pract 2011;9(1):5. DOI: 10.1186/1897-4287-9-5. PMID: 21819606.Imyanitov E.N., Moiseyenko V.M. Drug therapy for hereditary cancers. Hered Cancer Clin Pract 2011;9(1):5. DOI: 10.1186/1897-4287-9-5. PMID: 21819606.9. Schwartz G.F., Hortobagyi G.N. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26–28, 2003, Philadelphia, Pennsylvania. Breast J 2004;10(4):273–94.Schwartz G.F., Hortobagyi G.N. Proceedings of the consensus conference on neoadjuvant chemotherapy in carcinoma of the breast, April 26–28, 2003, Philadelphia, Pennsylvania. Breast J 2004;10(4):273–94.10. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29(9):e45. PMID: 11328886.Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29(9):e45. PMID: 11328886.11. Kurebayashi J., Yamamoto Y., Kurosumi M. et al. Loss of BRCA1 expression may predict shorter time-toprogression in metastatic breast cancer patients treated with taxanes. Anticancer Res 2006;26(1):695–701. PMID: 16739340.Kurebayashi J., Yamamoto Y., Kurosumi M. et al. Loss of BRCA1 expression may predict shorter time-toprogression in metastatic breast cancer patients treated with taxanes. Anticancer Res 2006;26(1):695–701. PMID: 16739340.12. Mahmoud A.M., Macias V., Al-Alem U. et al. BRCA1 protein expression and subcellular localization in primary breast cancer: automated digital microscopy analysis of tissue microarrays. PLoS One 2017;12(9):e0184385. DOI: 10.1371/journal.pone.0184385. PMID: 28863181.Mahmoud A.M., Macias V., Al-Alem U. et al. BRCA1 protein expression and subcellular localization in primary breast cancer: automated digital microscopy analysis of tissue microarrays. PLoS One 2017;12(9):e0184385. DOI: 10.1371/journal.pone.0184385. PMID: 28863181.13. Egawa C., Motomura K., Miyoshi Y. et al. Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers. Breast Cancer Res Treat 2003;78(1):45–50. PMID: 12611456.Egawa C., Motomura K., Miyoshi Y. et al. Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers. Breast Cancer Res Treat 2003;78(1):45–50. PMID: 12611456.14. Lafarge S., Sylvain V., Ferrara M., Bignon Y.J. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001;20(45):6597–606. DOI: 10.1038/sj.onc.1204812. PMID: 11641785.Lafarge S., Sylvain V., Ferrara M., Bignon Y.J. Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway. Oncogene 2001;20(45):6597–606. DOI: 10.1038/sj.onc.1204812. PMID: 11641785.15. Mullan P.B., Quinn J.E., Gilmore P.M. et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001;20(43):6123–31. DOI: 10.1038/sj.onc.1204712. PMID: 11593420.Mullan P.B., Quinn J.E., Gilmore P.M. et al. BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001;20(43):6123–31. DOI: 10.1038/sj.onc.1204712. PMID: 11593420.16. Quinn J.E., Kennedy R.D., Mullan P.B. et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003;63(19):6221–8. PMID: 14559807.Quinn J.E., Kennedy R.D., Mullan P.B. et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003;63(19):6221–8. PMID: 14559807.17. Harte M.T., Gorski J.J., Savage K.I. et al. NF-κB is a critical mediator of BRCA1- induced chemoresistance. Oncogene 2014;33(1):713–23. DOI: 10.1038/ onc.2013.10. PMID: 23435429.Harte M.T., Gorski J.J., Savage K.I. et al. NF-κB is a critical mediator of BRCA1- induced chemoresistance. Oncogene 2014;33(1):713–23. DOI: 10.1038/ onc.2013.10. PMID: 23435429.18. Sau A., Lau R., Cabrita M.A. et al. Persistent activation of NF-κB in BRCA1-deficient mammary progenitors drives aberrant proliferation and accumulation of DNA damage. Cell Stem Cell 2016;19(1):52–65. DOI: 10.1016/j.stem.2016.05.003. PMID: 27292187.Sau A., Lau R., Cabrita M.A. et al. Persistent activation of NF-κB in BRCA1-deficient mammary progenitors drives aberrant proliferation and accumulation of DNA damage. Cell Stem Cell 2016;19(1):52–65. DOI: 10.1016/j.stem.2016.05.003. PMID: 27292187.